Back to Search
Start Over
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
- Source :
-
Acta Haematologica . Mar2019, Vol. 141 Issue 2, p107-110. 4p. 1 Diagram. - Publication Year :
- 2019
-
Abstract
- Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have dismal outcomes. Novel immunotherapies targeting CD19, including the bispecific T-cell engager blinatumomab and chimeric antigen-receptor T (CAR-T) cells, have revolutionized the treatment of R/R B-ALL. Robust response rates to CAR-T cell therapy after blinatumomab have recently been reported, but it is unknown whether blinatumomab can be effective following failure of anti-CD19 CAR-T cell therapy. Herein, we describe a patient with Philadelphia chromosome-positive B-ALL who relapsed after CD19-directed CAR-T therapy, but subsequently responded to the combination of blinatumomab and the tyrosine kinase inhibitor ponatinib, with the achievement of a complete remission lasting 12 months. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00015792
- Volume :
- 141
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Acta Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 135036675
- Full Text :
- https://doi.org/10.1159/000495558